Rationale, Opportunities, and Reality of Biosimilar Medications

N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125.

Authors

Gary H Lyman¹, Robin Zon¹, R Donald Harvey¹, Richard L Schilsky¹

Affiliation

¹ From the Fred Hutchinson Cancer Research Center, Seattle (G.H.L.); Michiana Hematology Oncology, Mishawaka, IN (R.Z.); Emory University, Atlanta (R.D.H.); and the American Society of Clinical Oncology, Alexandria, VA (R.L.S.).

PMID: 29791832
DOI: 10.1056/NEJMhle1800125

No abstract available

MeSH terms

Attitude of Health Personnel
Biosimilar Pharmaceuticals* / economics
Biosimilar Pharmaceuticals* / therapeutic use
Drug Approval*
Drug Industry / legislation & jurisprudence
Drug Labeling / legislation & jurisprudence
Government Regulation
Health Knowledge, Attitudes, Practice
Humans
United States
United States Food and Drug Administration

Substances

Biosimilar Pharmaceuticals